Abstract: Anti-cancer immune-stimulating therapies have shown inconsistent results when used in humans. The present disclosure provides methods of using eosinophil-depleting agents to increase the therapeutic activity of anti-cancer immune-stimulating therapies. The present disclosure also provides methods of identifying subjects susceptible to respond to anti-cancer immune-stimulating therapies based on their ability to reduce the number of tumor regulatory T cells.

Abstract: There is provided a stromal antigen-presenting cell capable of antigen presentation in the context of MHC II. When stimulated with IFN? the stromal cell expresses B7-H1 and/or CD80. These stromal cells can be used to generate an immune response in an animal.

Abstract: There is provided a stromal antigen-presenting cell capable of antigen presentation in the context of MHC II. When stimulated with IFN? the stromal cell expresses B7-H1 and/or CD80. These stromal cells can be used to generate an immune response in an animal.

Abstract: The present invention relates to an immuno-therapy conjugate which comprises A-c-B wherein: A and B are different and are compounds selected from the group consisting of cytokines, chemokines, interferons, their respective receptors or a functional fragment thereof; and c is a linker consisting of a bond or an amino acid sequence containing from 1 to 100 residues. The present invention also relates to a vaccine adjuvant comprising the immuno-therapy conjugate of the present invention. The present invention further relates to a method of reducing tumor growth, for inhibiting a viral infection and for improving immune response in a patient.

Abstract: The present invention relates to genetically-engineered bone marrow stromal cells and method of preparation thereof for ex vivo delivery of protein and peptides of interest into human or animals. The method includes forming a bone marrow stromal cell expression system in vitro and administering the expression system to a human or animal recipient. The invention relates also to implants colonized by bone marrow stromal cells. In accordance with the invention, the implants comprise a matrix which can be composed of a large variety of biocompatible and biodegradable products, and stromal cells which are integrated into the matrix as such or under genetically-engineered forms. Genetically-engineered bone marrow stromal cells or cell colonized implant are also useful for tissue repair and tissue synthesis, as for angiogenesis.